---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-244590"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2024-10-28T23:59:59+00:00"
generated_at: "2026-05-30T09:49:00.537046+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tyra Biosciences receives FDA clearance for Phase 2 trial of TYRA-300 in achondroplasia

## Summary
- FDA cleared IND for TYRA-300 Phase 2 trial (BEACH301) in children with achondroplasia ages 3-10.
- BEACH301 is multicenter, open-label, dose-escalation/dose-expansion with two cohorts (naïve and prior therapy), up to 10 per dose level.
- Primary endpoints: safety/tolerability and annualized growth velocity; secondary: height z-score, proportionality, PK.
- First patient dosing expected Q1 2025; also plans IND for TYRA-300 in NMIBC by year-end 2024.

## SEC filing metadata
- accession: 0001193125-24-244590
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2024-10-28T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000119312524244590/0001193125-24-244590-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000119312524244590/d895225d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-244590
- JSON: https://secwatch.observer/filing/0001193125-24-244590.json
- Plain text: https://secwatch.observer/filing/0001193125-24-244590.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.